Tranexamic acid
| Type of posting | Offer |
| Category | Pharmaceutical Intermediates |
| City / Port | Wuhan, CN, China |
| Description | Tranexamic acid Name: Tranexamic Acid The pharmaceuticals category: hemostatic Weight: 157 MF: C8H15NO2 Appearance: white crystalline powder Content: ≥ 99% Implementation of the standards: CP2005 BP2003 EP5 JP14 CAS.: 1197-18-8 Packaging: 25 kg / drum Appearance: white crystal or crystalline powder, odorless and tasteless. This product is soluble in acid-base, dissolved in water, practically insoluble in acetone, methanol. Uses: for low dose can inhibit the activation of plasminogen. High dose is also directly inhibit the lytic enzyme activity of the plasminogen protein, can also inhibit trypsin and chymotrypsin activity. The goods and high affinity lysine binding region of plasminogen or plasmin, so that competitive inhibition of fibrin lysine and plasminogen binding, thereby inhibiting the cleavage of a fibrin clot, a hemostatic effect . For the treatment of bleeding caused by hyperfibrinolysis, such as cirrhosis intraoperative bleeding. Also can be used for recurrent epistaxis, eye trauma bleeding, recurrent subarachnoid hemorrhage. Hemophilia, hereditary antiplasmin deficiency tooth before and after the administration, can reduce the amount of the infusion of coagulation factor. |
| Date | 2013 Feb 27, 06:02 |